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Abstract: Currently, we are facing increasing demand to develop efficient systems for the detection
and treatment of diseases that can realistically improve distinct aspects of healthcare in our society.
Sensitive nanomaterials that respond to environmental stimuli can play an important role in this task.
In this manuscript, we review the clinical trials carried out to date on thermosensitive nanomaterials,
including all those clinical trials in hybrid nanomaterials that respond to other stimuli (e.g., magnetic,
infrared radiation, and ultrasound). Specifically, we discuss their use in diagnosis and treatment
of different diseases. At present, none of the existing trials focused on diagnosis take advantage of
the thermosensitive characteristics of these nanoparticles. Indeed, almost all clinical trials consulted
explore the use of Ferumoxytol as a current imaging test enhancer. However, the thermal property
is being further exploited in the field of disease treatment, especially for the delivery of antitumor
drugs. In this regard, ThermoDox®, based on lysolipid thermally sensitive liposome technology
to encapsulate doxorubicin (DOX), is the flagship drug. In this review, we have evidenced the
discrepancy existing between the number of published papers in thermosensitive nanomaterials and
their clinical use, which could be due to the relative novelty of this area of research; more time is
needed to validate it through clinical trials. We have no doubt that in the coming years there will
be an explosion of clinical trials related to thermosensitive nanomaterials that will surely help to
improve current treatments and, above all, will impact on patients’ quality of life and life expectancy.
Keywords: thermosensitive nanomaterials; USPIO; magnetic nanoparticles; Ferumoxytol; gold
nanoparticles; ThermoDox
1. Introduction
Nowadays, there is a real need to seek out more efficient systems for the diagnosis and treatment
of many diseases and hence achieve better overall health in our society. Sensitive nanomaterials
that can respond to exact stimuli are part of an important strategy in many biomedical fields like
drug delivery, biosensing, and biomaterials [1,2] These materials can be functionalized to respond
to temperature, pH, light, electric field, magnetic field, radiofrequency and ultrasound, amongst
many others [3,4]. Specifically, thermosensitive nanomaterials are promising in disease treatment and
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diagnosis due to their capacity to aim at pre-selected sites when simulated in a certain temperature
range [5]. Amid disparities of diversified biomedical applications, thermosensitive nanomaterials have
remarkable features, which make them strong candidates for use in medical applications such as drug
delivery, diagnostic devices, and thermal therapy.
The field of thermal therapy has grown exponentially in recent years. Indeed, several studies have
been registered using traditional hyperthermia, in combination with chemotherapy and/or radiation
therapy, for the elimination of many types of tumors [6–8]. In magnetic hyperthermia, which has
reduced side effects, tumor cells receive heat through the use of magnetic nanoparticles (MNPs) and an
alternating magnetic field (AMF) [9]. AMF heating promotes deep tumor penetration and temperature
regulation [10]. MNP-based thermal therapy has remarkable advantages over traditional thermal
therapies such as (i) innocuous penetration of frequencies produced by MNPs, (ii) homogenous heat
generation, (iii) the possibility of inducing antitumoral immunity, and (iv) the development of a
multi-modality device providing thermal therapy and magnetic resonance imaging (MRI) [11]. Among
different clinical therapies, magnetic fluid hyperthermia (MFH)-based thermotherapy has received
great interest as an antitumor strategy, wherein ultrasmall superparamagnetic iron oxide nanoparticles
(USPIOs) are principally used to induce localized therapeutic heat (reaching 42−45 ◦C) inside the
tumors [12]. Also, the heat generated from specific nanoparticles (i.e., gold nanoparticles (GNPs)) can
be utilized to eradicate/damage cancerous cells by photothermal therapy (PTT) [13]. When a laser is
focused on a tissue, the photons are absorbed by the cellular and intercellular areas and their energies
are converted into heat, inducing cellular death. Unlike traditional hyperthermia, PTT is produced in
the area directly surrounding nanoparticles, and local temperatures can rise, in very short time scales,
by tens or hundreds of degrees Celsius above physiological temperature. This would help to reduce
the side effects of the antitumor treatments because the treatment can be directed to the targeted tissue.
Controlling the application of thermal energy to living tissues is a great challenge, which is driving
the development of many devices and treatment techniques, both at preclinical and clinical levels [14].
The trend is to improve non-invasive monitoring methods in contrast to existing techniques, such as
tissue biopsies, that are based on destructive/invasive methods.
Non-invasive procedures like positron emission tomography (PET) and MRI lack the specificity
to be a feasible alternative to cell tracing. Single photon emission computed tomography, even
though it permits non-invasive tracking of in vivo bio-dissemination of radiotracers at picomolar
concentrations, has several disadvantages (e.g., limited spatial resolution, lack of anatomical details for
reference, etc.) that make it difficult to target the exact location of lesions. The combination of different
imaging modalities using multimodal probes can be of great interest in molecular imaging [15]. This
synergistic combination provides improved visualization of biological targets, and obtains information
on all aspects of cell or tissue structure and function, which is hard to obtain by a single imaging
modality [16].
New devices based on thermal nanoparticles combined with multi-modality imaging would
simplify non-invasive monitoring of treatments, since they could allow simultaneous dynamic imaging
of both structure and function and directly provide valuable information on pharmacokinetics and
drug metabolism. Moreover, nanomaterials can provide information on the biological state of cells in
addition to their physical location [17].
Until now, many types of nanomaterials have been used to build thermosensitive nanosystems
for therapy and diagnosis, such as inorganic nanoparticles, carbonaceous materials, and liposomal
formulations [5,18,19].
1.1. Inorganic Nanoparticles
Among the extensive variety of inorganic nanoparticles reported in the literature, MNPs, USPIOs,
and GNPs experience increased relevance as thermosensitive nanomaterials for biomedicine [20,21].
MNPs are known to be very promising for biomedical treatments [22]. In particular, iron oxide
nanoparticles (IONs) possess an inherit elemental composition that makes them biocompatible and
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degradable by nature [23]. IONs can be produced in very small sizes (<40 nm), with uniform size
distribution, superparamagnetic nature, possibility of functionalization with different molecules (drug
molecules, fluorescent compounds [24–26]), solubility in water along with a high magnetic moment.
These are simply some of the characteristics that make these materials attractive for many applications,
e.g., hyperthermia and magnetic resonance enhancement. The combination of magnetic and other
properties in one single nanoparticle can create a path to new multifunctional nanomaterials that
display multimodal properties [27,28]. For example, externally applied magnetic fields can be used to
address some specific targeted functionalization such as the controlled release of drugs in desired areas,
gathering the nanocomposites in a specific region for diagnosis or treatment and, finally, eradicating
them at the end of the whole procedure [29,30]. It is also important to point out that multimodal MNPs
can also open the access to the monitoring of all the possible steps included in the treatments by taking
advantage of numerous imaging procedures like MRI and computed tomography (CT) [31,32].
Among the various MNPs, the USPIOs are very useful for biomedical applications [33,34]. The
USPIOs are magnetite (Fe3O4) and/or maghemite (γ-Fe2O3) particles, usually coated with different
surface coating molecules, such as citrate, polymers, and silica. This hydrophilic coating helps the
water dispersibility and improves the colloidal stability and biocompatibility of the USPIOs [35,36].
In the family of nanoparticles, GNPs are unlike any others, displaying some unique optical
properties, where the origin is due to an electromagnetic phenomenon called surface plasmon
resonance (SPR) [37]. SPR depends on several characteristics of GNPs like, for example, their size,
composition, shape, etc. [38]. The control of SPR effect on GNPs has been shown to lead to important
bioimaging applications and/or photothermal agents [39,40]. Last but not least, there is another
quite interesting property of GNPs, which is the heat generation after absorbing infrared light. After
excitation by the light source, the nanoparticles face the possibility to dissipate the heat into their
surroundings, melt, or even cause structural damage. This unique property has been exploited for PTT
applications [41,42].
1.2. Carbon-Based Nanomaterials
Other types of inorganic materials actively investigated in biomedical applications are
carbon-based nanomaterials (CBNs) [43]. One popular two-dimensional (2D) CBN is a derivative
of graphite, termed graphene, a single layer of sp2-bonded carbon atoms. The main characteristics
of these materials are high mechanical strength and excellent thermal and electrical conductivity.
Graphene in its oxidized form, graphene oxide (GO), exhibits oxygen atoms on the edges and basal
planes of its structure. The functional groups with oxygen atoms (epoxy, hydroxyl, carboxylic and
carbonyl, etc.) turn out to be ideal binding sites for different molecules, such as polymers and biological
molecules [44], and increases its hydrophilicity in comparison to graphene. It has been reported that
GO is also non-toxic and biocompatible at low concentrations [45]. Another interesting feature is a
high photothermal conversion capability in the near-infrared (NIR) wavelength region. Thus, the
combination of strong absorption and heat transfer can be used to kill tumor cells directly [46]. In
addition, incorporating GO nanosheets into thermosensitive hydrogels may reveal some novel and
interesting applications. The main advantage of a thermosensitive hydrogel is that it is a viscous liquid
at low temperature, which allows easy handling, incorporation of cells or biomolecules, and finally
injection in a minimally invasive manner. Importantly, shape stability at the injection site is warranted
by their gelation at body temperature. Incorporating CBNs improves their fracture strength and, in
some cases, the elastic modulus as well, which is a requirement for load-bearing applications. The
kinetics of the temperature response can be tuned by the quality and quantity of the filler, thereby
broadening their possible applications as sensors and drug delivery systems.
1.3. Liposomal Formulations
In addition to inorganic materials, thermosensitive liposomes (TSLs) are also interesting
instruments for drug delivery [24,47]. Liposomes are spherical vesicles composed of a membrane
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bilayer, usually constituted of phospholipids and an aqueous core [48]. Conventional liposomes
are approved for use as delivery systems for clinical use in oncology [49]. However, the liposomes
present poor penetration and a limited drug release factor in the tumor area. Otherwise, upon
administration, circulating TSLs are activated locally under conditions of mild hyperthermia by
increasing the temperature (to 40–41 ◦C) using an external heat source [50]. The increase of the
temperature causes compositional changes in the liposomal membrane, creating openings that permit
the release of the encapsulated drug. These thermo-devices favor the specific release of the largest
amount of cytotoxic agent to a heat-treated tumor site, limiting the injury to the surrounding normal
tissue [51]. To overcome these limitations, TSLs have been developed as new controlled drug release
systems [52]. ThermoDox®, a TSL containing DOX, is the only TSL formulation to arrive at drug
development. In the few last years, research has focused on solving the limitations associated with the
ThermoDox®formulation, such as poor circulation lifetime or the membrane permeability of DOX for
different diseases [53]. In this regard, Lindner et al. developed new TSLs with prolonged liposome
circulation time for mild hyperthermia, and showed an increased plasma half-life for the loaded drug
with t1/2 = 9.6 h in hamsters and t1/2 = 5.0 h in rats dependent on changes in composition of TSLs [54].
Limmer et al. showed an increase in plasma half-life of 0.53 to 2.59 h for gemcitabine (GEM) when the
size of TSLs was increased [55]. Furthermore, the development of TSLs loaded with non-membrane
permeable drugs (e.g., cisplatin (HTLC) [56], GEM, oxaliplatin [57]) allows their use for different
diseases that cannot be treated with DOX (e.g., breast, ovarian, cervical, gastric cancers). Moreover,
new applications of the liposomal formulations will open new biomedical possibilities. [58,59]. For
example, the synergy of TSLs and magnetic resonance-guided drug delivery will open the possibility
to target desired injured sites and online monitoring at the same time [60,61]. This is just one example
of the extraordinary true theranostic nature of thermosensitive liposomes, that is the ability to combine
specific targeted therapy based on specific targeted diagnosis. In this regard, Rizzitelli et al. [62]
published a preclinical study describing a novel protocol for the DOX release from TSLs monitored
by MRI in a breast cancer mouse model. In addition, DI-TSLs (DOX and indocyanine green (ICG)
loaded TSLs) capable of responding to NIR were manufactured. This theranostic system allows the
control of the release of drugs from TSLs (PTT for hyperthermia drug release) and uses fluorescence
of the same ICG to continuously monitor the drug-release, biodistribution and antitumor efficacy
of the DI-TSL system in the body [63]. Recently, a microfluidic chip has been developed capable of
adjusting the temperature rise for the drug control release by TSL. This system allows procedures
such as cytometric analysis and AFM scanning, as well as presenting small size, biocompatibility and
low cost [64]. Table 1 lists some of the recent publications related to the development of new TSLs
formulations and new applications.
Next, we will focus on a review of the clinical trials carried out to date with thermosensitive
nanomaterials including all those clinical trials in which the nanomaterials of interest are hybrid and
also respond to other stimuli (e.g., magnetic, infrared radiation and ultrasound). Specifically, we
discuss their use in both diagnosis and treatment of different diseases without forgetting those already
approved by Food and Drug Administration (FDA) for clinical use (Figure 1).
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Table 1. New TSLs systems developed for cancer treatment and diagnosis.
Type of TSLs Drug Improvement Use Ref.
Liposome formulations of
HTLC
HTLC Treatment of cervical
carcinoma
Treatment [56]
Liposomal formulations with
drug
GEM
DOX
Increased drug
plasma half-life
Treatment [55]
[65]
Multi-modal thermo-sensitive
polymer-modified liposomes
(MTPLs)
MnSO4,
rhodamine, DOX
Monitor drug delivery in
cancer therapy
Diagnosis [66]
Liposomal ICG ICG Deliver ICG as the NIR in the
treatment of triple negative
breast cancer
Treatment [67]
TSLs loaded with drug and
fullerene decorated with IONs
ICG, DOX Multifunctional TSLs showing
radiofrequency release and
MRI for tumor therapy
Diagnosis
and treatment
[60]
TSLs loaded with drugs and
mesoporous silica
nanoparticles
ICG, DOX Multifunctional nanoplatform
for integrate diagnosis and
treatment (photodynamic
therapy and PTT) for cancer
Diagnosis
and treatment
[68]
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2. Clinical Trials and Marketed Thermosensitive Nanomedicines
Several clinical trials are currently being conducted or have been completed in a wide spectrum
of pathologies (https://clinicaltrials.gov/). Its use is focused n both treatment and diagnosis of
different diseases and some of them have been approved by regulatory bodies. We have used the
terms “Thermosensitive”, “USPIO”, “Magnetic nanoparticles”, “Ferum xytol”, “gold nanoparticles”
or “ThermoDox” as keywords when looking for this information. Whe conducting our search, we
have observed that a discrepancy exists between the number of published papers in thermosensitive
nanomaterials and the number of nanomaterials i clinical use (Figure 2).
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Figure 2. Number of publications (blue) versus clinical trials (red) related to thermosensitive
nanomaterials, USPIOs, MNPs, GNPs, Ferumoxytol and ThermoDox®. Data reported here reflect
manuscripts available through PubMed database and clinicaltrials.gov up to November 2018.
2.1. Thermosensitive Nanomaterials for Disease Diagnosis
Until now, the thermosensitive nanomaterials used in the diagnosis of different pathologies do
not take advantage of the thermal characteristics of these materials. Indeed, among all thermosensitive
nanoparticles, the majority of clinical trials have been registered with USPIOs as contrast agents and
only one clinical trial uses MNPs to separate mature sperm from immature ones. However, clinical
trials have begun to be recorded in order to investigate the safety of novel nanoparticles such as carbon
black and graphene nanoparticles [69] (Table 2).
2.1.1. Ferumoxytol as a Current Imaging Test Enhancer
USPIOs attracted extensive research efforts for cellular imaging applications and their clinical
research has been recently updated by Wang and Idee [70]. Feru oxytol, an USPIO system developed
as an MRI contrast agent in 2000, is better known as a therapeutic agent for the treatment of iron
deficiency anemia (IDA) in the setting of chronic kidney disease (CKD). Nevertheless, in recent
years, ferumoxytol has regained interest as an agent for MRI enhancement and most of the clinical
trials carried out on nanothermal materials focus on their use in the diagnosis of several pathologies.
Ferumoxytol, has many characteristics that make it an attractive candidate to be a good contrast
agent for vascular and perfusion-weighted MRI (i) easy administration through a rapid bolus, (ii) long
intravascular half-life (14–15 h), (iii) less limited by idiosyncratic and allergic reactions in comparison to
other USPIOs; (iv) provides a strong T1- and T2-signal on MRI and is taken up by cells in bone marrow.
Moreover, ferumoxytol is an iron-based agent that can be an alternative to gadolinium-based contrast
agents (GBCAs) in patients with compromised renal function since it does not cause nephrogenic
systemic fibrosis [71]. It has been shown that feru oxytol is finally taken up by macrophages/the
reticuloendothelial system in the spleen, liver, and lymph nodes. This uptake mechanism is being used
as a novel imaging technique for tumors, vascular lesions, and lymph nodes. Currently, many clinical
trials are being conducted to determine its efficacy and safety as an intravenous contrast agent in MRI.
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a. Cancer Diagnosis
In the field of oncology, there are currently several investigations that aim to use
ferumoxytol-enhanced MRI to diagnose primary and metastatic tumors. USPIOs do not directly
identify the tumoral cells, they help to improve the resolution of the MRI image, which makes it easier to
make a differential diagnosis that indirectly, and together with the results obtained through other tests
such as steady-state blood volume mapping, indicates the state of the lesion. Although visualization of
the lesion with USPIOs is generally similar to GBCAs, differences in improvement patterns, based on
the breakdown of the blood-brain barrier marker, can help the differential diagnosis [72]. Parenchymal
improvement is best seen in the delayed phase, 24 h after the injection of USPIOs as the extravasation of
large molecules is slow. USPIOs improve the delimitation of the edges and allows the evaluation of the
internal morphology of the lesion as it has been reflected in several MRI sequences weighted in T1 used
clinically. The decrease in the signal in the T2-weighted images in the delayed phase can indicate great
local USPIO levels or retention in tumor-associated macrophages. The low T1 and T2 improvement
together can help differentiate tumor necrosis (extracellular iron) from solid tumor (intracellular iron).
Perfusion MRI and steady-state blood volume mapping can also enhance tumor classification by
recognizing the most malignant area for surgical selection and monitoring of therapy [73]. There are
currently several clinical trials that aim to use ferumoxytol-enhanced MRI to diagnose primary and
metastatic tumors. This is the case with the phase II trial study that will analyze the effectiveness of
ferumoxytol, in comparison to gadolinium, in measuring tumors in patients undergoing treatment for
brain tumors or other tumors that have metastasized to the brain [74]. In addition, another clinical
trial is underway to determine by MRI if ferumoxytol can provide more data to understand the spread
of head and neck squamous cell carcinoma and melanoma [75], breast cancer, and prostate cancer [76].
Moreover, another clinical trial focuses on the analysis of how well ferumoxytol-enhanced MRI
works in imaging lymph node metastases in patients with different types of cancers such as esophageal
cancer [77], advanced rectal cancer [77,78], prostate [79], bladder, and kidney cancers [80], breast
cancer [81], and brain neoplasm in both adults and children [82–85].
In addition, ferumoxytol-enhanced MRI can serve not only in the detection of cancer cells but also
in the differentiation between malign and infectious diseases. In fact, Macrophages play an important
role in the pathogenesis of inflammation. After human intravenous (IV) injection, superparamagnetic
iron oxide nanoparticles (SPIOs) arrive at inflammation sites where their small size of (10–30 nm)
enables them to leak through permeable capillaries (5–100 nm) into inflamed tissues. Then they are
phagocytosed by macrophages displaying prolonged T2 and T2* effects on contrast-enhanced MR
images in macrophage-infiltrated tissues [73]. Seyfer et al. [86] found that abscesses (infectious masses)
could be differentiated from viable tumor because they displayed a smaller contrast-to-noise ratio
than neoplasia when imaged using a T2*-weighted MRI sequence with SPIOs. Twenty-four hours
after the USPIO-injection, no changes were observed in VX2 carcinomas, whereas a mean reduction
of the contrast-to-noise ratio (CNR) of approximately 90% was noticed in abscesses. In addition to
that, necrotic tumors can also be differentiated from viable tumors and from abscesses as they present
mixed behavior after USPIO injection. On histopathologic examination, abscess and necrotic parts of
the tumor were found to include iron-containing monocytes demonstrating that the reduction in CNR
was caused by USPIO-tagged monocytes. In this context, researchers from Stanford University School
of Medicine conducted a pilot trial to analyze whether ferumoxytol-enhanced MRI can be used in the
differentiation between bone sarcomas and osteomyelitis [87]. Furthermore, ferumoxytol-enhanced
MRI can serve also to assess response to therapy since it has been seen that after treatment of brain
tumor with chemoradiotherapy or radiation, augmented edema and contrast improvement on MRI
may either represent (i) tumor progression since the increase of the tumor mass indicates the failure of
the ongoing treatment, or (ii) pseudoprogression, which results in a subacute inflammatory reaction
caused by the treatment without underlying tumor [88]. Being able to differentiate between these two
procedures is a key element for patient survival. In this sense, some pilot trials study the effectiveness
of ferumoxytol-MRI in assessing response to pembrolizumab in patients with tumors on the brain
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originating from melanoma and glioblastoma metastasis [89], in patients with glioblastoma multiforme
receiving temozolomide and radiation therapy [90] and in patients with high grade glioma treated
with a bevacizumab and dexamethasone [91]. Diagnostic procedures, such as ferumoxytol MRI, may
help measure a patient’s response to antitumor drug treatment.
b. Non-tumor Pathology Diagnosis
Furthermore, ferumoxytol is also being studied for its applicability as a contrast agent for MRI of
non-tumor pathologies such as myocardial Infarction [92], Hereditary Hemorrhagic Telangiectasia [93],
Type 1A diabetes [94,95], Renal Transplant Rejection [96] and Osteonecrosis [97]. A randomized
phase II trial studies how well gadolinium and ferumoxytol MRI works in diagnosing patients with
abnormalities in the Central Nervous System (CNS) [98]. Determining the extent of inflammation
associated with pathologies in the CNS may be useful both for diagnosis, prognosis, and monitoring
the treatment response of current and future immunotherapies. In this sense, researchers investigate
the safety of ferumoxytol as a contrast agent to be used in the identification of neuroinflammation in
multiple sclerosis (MS) patients [99]. For that, they want to (i) investigate its safety as determined by a
lack of long-term signal change in healthy volunteers (HV) and people with MS; (ii) investigate if this
drug improvement can be detected in MS lesions on 7-tesla (T) MRI; and (iii) analyze the special and
temporal enhancement patterns of ferumoxytol compared to gadolinium contrast and gradient-echo
imaging in MS lesions. A similar trial was carried out on human patients with epilepsy [100].
Human Immunodeficiency Virus (HIV)-associated neurocognitive disorders (HAND) have a
significant impact on morbidity and quality of life of patients. HAND remains a chronic issue despite
effective combination antiretroviral therapy. It is believed that Monocytes/macrophages play a
critical role in the pathogenesis of this pathology. Neuroimaging HIV research has not focused on
assessing Monocytes/macrophages-mediated inflammation in the brain. Hence, clinical trials are
being conducted to find out if ferumoxytol-based imaging can identify ongoing inflammation due to
perivascular monocytes/macrophages, which are thought to represent a key pathological correlate of
HAND [101,102].
On the other hand, ferumoxytol can be used to enhance Magnetic Resonance Angiography (MRA).
Conventional vascular imaging techniques are frequently contraindicated in patients with CKD due to
their relative invasiveness and risk. Computed tomography angiography (CTA) requires nephrotoxic
iodinated contrast and radiation that can cause a deterioration of renal function and even cause the
need for a dialysis. GBCAs for MRA have been related with rare nephrogenic systemic fibrosis disease.
Alternative methods of imaging also have drawbacks such as (i) increased risk of complications from
conventional invasive catheter angiography, (ii) MRA without contrast permits visualization of smaller
arteries but is less precise for larger vascular structures and (iii) ultrasound is frequently not suitable
for evaluation of the deep vessels of the abdomen and pelvis. In this sense, a ferumoxytol-enhanced
MRA phase 4 clinical trial is being undertaken [103]. Other clinical trials for coronary artery disease,
peripheral arterial disease [104] and cerebrovascular disorders [105] are being carried out.
2.1.2. Magnetic Nanoparticles for Sperm Sorting
MNPs are also used in the field of fertility. In fact, a recent clinical trial was initiated in September
2018 and aims to achieve sperm separation by MNPs for Intracytoplasmic sperm microinjection (ICSI)
cycles with teratozoospermia and women of over 35 years of age [106]. Women over 35 years old are
likely to suffer from impaired oocyte repair capacity. Teratozoospermia is a condition that reflects
morphological affection of sperm. These spermatozoa would add an extra burden to the oocyte after
ICSI. The hypothesis of this research is whether the selection of mature sperm by a MNPs protocol
would provide a more competent sperm to a likely affected oocyte that would improve the ICSI results.
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Table 2. Current clinical trials of thermosensitive nanomaterials for diagnosis of various diseases available on clinicaltrials.gov up to November 2018.
Pathology Interventions ClinicalTrials ID Phase Date (First–Last Posted) Ref.
Blood Biomarkers Vasodilation Blood
Clotting Lung Function Healthy Volunteers
- Diesel exhaust particulate
NCT03659864 Not applicable September 2018–still
active
[69]
- Carbon nanoparticles
- Small graphene oxide
- Ultrasmall graphene oxide
Metastatic and Primary Brain Neoplasm
- Ferumoxytol
NCT00659126 Phase 2 2018–still active [74]- 3 Tesla MRI
- Dynamic Contrast-Enhanced MRI
Head and Neck Cancer
- Ferumoxytol
NCT01895829 Early Phase 2013–still active [75]- MRI
Solid Tumors
Ferumoxytol followed by MM-398 NCT01770353 Phase 1 2013–still active [76]ER/PR Positive Breast Cancer
Active Brain Metastasis
Rectal Cancer (Stage III)
Esophageal Cancer (Stage II–III)
- Ferumoxytol
- MRI
- PET/CT
NCT03280277 Phase 2 2017–still active [77]
Cancer of Lymph Node - Feraheme NCT01815333 Not applicable 2013–still active [78]- MRI
Prostate Cancer Drug: Ferumoxytol NCT01296139 Phase 1 2011–2018 [79]
Prostate Cancer
Bladder Cancer
Kidney Cancer
- Ferumoxytol
- MRI NCT02141490 Phase 2 2014–still active [80]
Breast Cancer - Ferumoxytol
NCT00087347 Not applicable 2013–still active [81]Prostate Cancer - MRI
Soft Tissue Sarcoma - Ferumoxytol
NCT00978562 Not applicable 2017–still active [82]Childhood Brain Neoplasm - MRI
Brain Injury - Ferumoxytol
NCT02452216 Early Phase 1 2015–2017 [83]CNS: Degenerative and Infectious Disorder - MRI
Childhood Brain Neoplasm - Ferumoxytol NCT03179449 Early Phase 1 2017–still active [84]- MRI
CNS
Brain Neoplasm
- Ferumoxytol
- 3 Tesla MRI
- Dynamic MRI
NCT02857218
NCT00103038 Not applicable 2005–still active
[107]
[85]
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Table 2. Cont.
Pathology Interventions ClinicalTrials ID Phase Date (First–Last Posted) Ref.
Bone Cancer
Chondrosarcoma
Ewing’s Sarcoma
- Feraheme
- MRI NCT01336803 Not applicable 2011–still active [87]
Glioblastoma - Pembrolizumab
NCT03347617 Phase 2 2017–still active [89]Malignant Primary and metastatic Brain
Neoplasm - Ferumoxytol
Melanoma - MRI
Adult Brain Glioblastoma
- Gadolinium
NCT00660543 Not applicable 2016–2017 [90]- Ferumoxytol
- MRI
Brain Neoplasms Ferumoxytol NCT00769093 Phase 1 2008–2017 [91]
Myocardial Infarction - Ferumoxytol NCT01323296 Not applicable 2011–2014 [92]- MRI
Hereditary Hemorrhagic Telangiectasia Feraheme MRI/MRA NCT02977637 Phase 1 2016–still active [93]
Diabetes Mellitus, Type 1 - Ferumoxytol NCT00585936 Not applicable 2008–2011 [94]- MRI
Type 1 Diabetes - Ferumoxytol NCT01521520 Not applicable 2012–still active [95]- MRI
Renal Transplant Rejection - Feraheme NCT02006108 Not applicable 2017–2018 [96]- MRI-GE Healthcare 3 Tesla magnet
Osteonecrosis
- Ferumoxytol
NCT02893293 Phase 4 2015–still active [97]- MRI
CNS Neoplasm
- Ferumoxytol
NCT03270059 Phase 2 2017–still active [98]- Gadolinium
- MRI
MS
- Ferumoxytol
NCT02511028 Early Phase 1 2015–still active [99]- MRI
Epilepsy - Ferumoxytol injection after focal epileptic seizure NCT02084303 Not applicable 2014–2018 [100]- MRI
HIV Dementia - Ferumoxytol NCT01665846 Phase 1 2012–2018 [101]
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Table 2. Cont.
Pathology Interventions ClinicalTrials ID Phase Date (First–Last Posted) Ref.
AIDS Dementia Complex - Ferumoxytol NCT02678767 2016-2017 Phase 2 [102]- MRI
Peripheral Arterial Disease - Ferumoxytol NCT00707876 Phase 2 2008–still active [104]- MRI
Cerebrovascular Disorders Quantitative MRI NCT03266848 Not applicable 2017–still active [105]
Infertility MNP Sperm Separation for ICSI Cycles NCT03666364 Not applicable September 2018–stillactive [106]
Acute Coronary Syndrome Immunomagnetic reduction by MNPs NCT02226523 Not applicable 2014–still active [108]
Lung Carcinoma
- Pembrolizumab
NCT03325166 Phase 2 2017–still active [109]- Ferumoxytol
- MRI
Childhood Brain Neoplasm - Ferumoxytol NCT03234309 Phase 2 2017–still active [110]- MRI
Nervous System Diseases - Ferumoxytol NCT00659776 Phase 2 2008–2012 [111]- MRI
Cardiac Transplant
Cardiac Sarcoid
Myocarditis
- Ferumoxytol
NCT02319278
Phase 2
2014–2017 [112]- MRI Phase 3
Pediatric Congenital Heart Disease - Ferumoxytol NCT02752191 Phase 4 2016–still active [113]- Gadofosveset
Coronary Artery Disease - Ferumoxytol NCT02954510 Phase 3 2016–still active [114]- MRI
- Coronary Artery Disease
- Atherosclerosis
- Stenting and micro
-infusion of GNPs NCT01436123 Phase 1 2011–2015 [115]
- Implantation of everolimus-eluting stent
Atherosclerosis - Ferumoxytol- MRI scan NCT01674257 Not applicable 2012–2013 [116]
Stroke - Radiation: 18f-Fluoride PET/CT- Radiation: 18F-Flurodeoxyglucose PET/CT
Ischemic Heart Disease
Iron oxide-labeled mesenchymal stromal
NCT03651791 Phase 1 August 2018–still active [117]MRI
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2.2. Thermosensitive Nanomaterials for Disease Treatment
Due to its characteristics, thermosensitive materials such as USPIOs, GNPs and
lyso-thermosensitive liposomal formulations could be new therapeutic tools whose applicability
is being demonstrated through various clinical trials (Table 3).
2.2.1. Iron Deficiency Anemia in Patients with Chronic Kidney Disease
Many formulations of USPIOs have already been approved by different countries for use in
patients with IDA in CKD [118]. These formulations vary according to their coatings, which enhance the
superparamagnetic properties of the nanoparticles in a different manner (Figure 3). The recommended
treatment is intravenous (IV) iron administration for hemodialysis patients and either oral or IV iron
for patients in CKD stages 1–5 who are anemic [119]. Currently, the efforts of researchers are focused
on conducting comparative studies to find out which formulation is the best in terms of efficacy and
side effects and which route of administration (IV or oral) is safer [120,121].
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Figure 3. USPIOs clinically approved or in clinical trials.
A meta-analysis of small randomized trials reported the efficacy of oral compared to IV on
hemoglobin response in CKD patients not on dialysis. In the short-term, one to three months, trials
(five of the six trials reported in this meta-analysis) informed that the mean increase in hemoglobin
with IV was 0.31 g/dL compared to oral iron. However, in a longer trial (six months), the authors
observed a mean decline in hemoglobin of 0.52 g/dL associated with IV administration. The long-term
safety of these modes of supplemental iron administration cannot be assessed because the duration of
most clinical trials was short [118].
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Recently, several clinical trials have been registered comparing ferumoxytol with other
superparamagnetic iron formulations. Ferumoxytol (Feraheme™, AMAG Pharma Inc., Lexington, KY,
USA) was approved for the treatment of IDA in adults with CKD in the United States and Canada
(Feraheme injection) [122] together with the European Union and Switzerland (Rienso, withdrawn
in 2015 for commercial reasons) [123]. Different to most other IV iron preparations, a complete cycle
of ferumoxytol (1.02 g) requires only two IV injections of 510 mg administered at a rate of up to
1 mL/s (30 mg/mL) between three and eight days apart. The two doses of ferumoxytol may have
advantages for both patients and health professionals. In this context, the results of a clinical trial
that examined rates of hypersensitivity reactions (HSRs) with IV iron formulations used to treat IDA
have been published. In this multicenter, double-blind and randomized clinical trial, researchers
compared the safety, and efficiency of ferumoxytol versus ferric carboxymaltose (FCM), aiming at the
incidence of moderate-to-severe HSRs, including anaphylaxis, or moderate-to-severe hypotension as
the primary end point and the incidence of moderate-to-severe HSRs, including anaphylaxis, serious
cardiovascular events, and death as the secondary end point. Ferumoxytol was not inferior to FCM for
both the primary and secondary composite safety end points, with an equivalent efficacy in increasing
hemoglobin despite a lower dose. However, with FCM treatment severe hypophosphatemia was
observed at higher rates [124].
Currently, a phase IV trial of repeated doses of ferumoxytol in comparison to iron sucrose for
the treatment of IDA in patients with CKD on hemodialysis has been completed. The objectives of
this study were to compare the efficacy and safety of repeat doses of IV ferumoxytol with IV iron
sucrose for the treatment of IDA in subjects with hemodialysis-dependent CKD [125]. In 2014, the
authors published their prelaminar results that indicate that ferumoxytol and iron sucrose show similar
effectiveness and side effect rates [119].
2.2.2. Cardiovascular Diseases
In the field of cardiology, some clinical trials have been registered. Plasmonic nanophotothermal
therapy is arousing great interest for atherosclerosis treatment. In fact, clinical trials are being carried
out, with the objective of analyzing the feasibility of nanoburning to eliminate and reverse the plaque,
especially in combination with stem cell technologies to achieve functional restoration of the vessel
wall [115,126]. Moreover, a recent clinical trial has been initiated to evaluate the ability to trace iron
oxide-labeled mesenchymal stromal cells (MSC) with MRI after NOGA-guided injection therapy into
the myocardium for the treatment of ischemic heart disease [117]. Thus, the ability of USPIO labeled
MSC injection to form new heart muscle cells and blood vessels in the myocardium, in order to improve
myocardial blood flow and reduce patients’ symptoms, will be analyzed.
2.2.3. Diabetes
A new drug based on the use of GNPs combined with peptide for the treatment of type I diabetes
is in its first clinical trial passes [127]. Type 1 diabetes appears when the immune system (body’s
own white blood cells) destroys the beta cells that produce insulin in the pancreas. The objective is to
develop a treatment that can slow or block this process by switching off the white blood cells causing
the damage. In this clinical trial researchers investigate the safety and side effect of C19-A3 GNP, a
peptide fragment related to insulin attached to GNPs, as a new therapeutic agent.
2.2.4. Cancer
In the field of oncology, perfect treatment is one that can be administrated under local anesthetic,
can effectively abolish tumor cells, its bystander effect is limited only to surrounding tissues, can be
repeatable, and adaptable to future discoveries such as anti-tumor molecular targeting. Magnetic
thermoablation, that involves direct injection of MNPs into the tumor, may be able to fulfill these
attributes. Magnetic thermoablation uses magnetic field to heat MNPs up to very high temperatures
that destroy tumoral cells. In prostate cancer this approach has been investigated in two different
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ways (i) using MNP thermotherapy alone [128] and (ii) in combination with permanent seed
brachytherapy [129]. In both trials, good tolerability and feasibility was shown using the first prototype
of an AMF applicator [130]. This innovative approach requires specific tools for thermal monitoring,
modeling techniques and quality control based on suitable imaging. Recently, an early phase 1 clinical
trial was registered to investigate whether the MNPs remain in their injection site. This is essential to
ensure the safety of this system. The consequences of their displacement can be fatal. Firstly, the MNPs
could move away from the tumor cells resulting in a poor effectiveness of treatment as targeted cells
will not be heated effectively. Secondly, the MNPs can reach sensitive structures around the prostate
such as nerves controlling erections, bladder, sphincter muscle controlling urine flow, etc. In this case,
the patient could develop serious side effects [131]. In this clinical trial, instead of heating the MNPs,
the investigators will use special scans and then surgery, they will determine the exact localization of
MNPs. Once determining its location in the injection site, the investigators will then be able to run
another study using magnetic thermoablation to treat prostate cancer patients.
Lyso-thermosensitive liposomal is another system for antitumor targeted drug delivery that is
being subjected to several clinical trials, with promising preliminary results. ThermoDox®(Celsion
Corporation, Lawrenceville, NJ, USA) is a long-circulating Lyso-Thermosensitive Liposomal
Doxorubicin (LTLD) approved for investigational use. ThermoDox®is a heat-activated drug delivery
system supplied by IV infusion and facilitates targeted delivery of a cytotoxic drug (DOX) to
tumors at temperatures exceeding 40 ◦C [132]. It was designed to be used in combination with
heat-based treatments, such as microwave hyperthermia, high-intensity focused ultrasound (HIFU), or
radiofrequency thermal ablation (RFA). The goal is to expand the effective treatment zone in order to
capture micrometastases, which are most commonly responsible for post-treatment disease recurrence.
In this context, TARDOX is a Phase 1 single center study of the administration of drugs directed by
ultrasound in patients with incurable liver tumors. This proof of concept study was designed to prove
the safety and feasibility of ThermoDox®unchained by mild hyperthermia induced by ultrasound
focused on liver tumors [133,134]. This early phase 1 study demonstrated that the combination of
LTLD and non-invasive ultrasound hyperthermia seemed to be clinically achievable, safe, and able
to improve intratumoral drug delivery, providing targeted chemo-ablative response in human liver
tumors that were intractable by standard chemotherapy [135]. A similar clinical trial is still ongoing for
pediatric refractory solid tumors [136]. Other phase 2 and 3 clinical trials are investigating the safety,
viability, and effectiveness of ThermoDox®combined with standardized radiofrequency ablation for
the treatment of both colon cancer liver metastasis [137] and hepatocellular carcinoma [138]; and
microwave hyperthermia in the treatment of recurrent regional breast cancer [139,140].
Table 3. Current clinical trials of thermosensitive nanomaterials for treatment of various diseases
available on clinicaltrials.gov until November 2018.
Pathology Interventions ClinicalTrialsID Phase
Date (First–Last
Posted) Ref.
CKD
- Ferumoxytol
NCT02997046 Phase 4 2016-still active [104]- MRA
Ischemic Heart Disease
- Iron oxide-labeled
mesenchymal stromal cells NCT03651791 Phase 1
August
2018-still active
[117]
- MRI
IDA - Ferumoxytol
NCT03619850 Phase 3
August
2018-still active
[120]Pediatric CKD - Oral Iron
IDA
Intravenous and Oral Iron NCT03657433 Phase 3 September 2018 [121]Pregnancy
IDA - Ferumoxytol
NCT01227616 Phase 4 2010-2017 [125]CKD - Iron Sucrose
- Stable Angina
- Heart Failure
- Atherosclerosis
- Multivessel Coronary
Artery Disease
- GNPs
- Iron-bearing nanoparticles
- Stenting
NCT01270139 Not applicable 2012-2017 [126]
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Table 3. Cont.
Pathology Interventions ClinicalTrialsID Phase
Date (First–Last
Posted) Ref.
Type 1 Diabetes
- C19-A3 GNP (peptide
fragment related to insulin
attached to GNPs)
NCT02837094 Phase 1 2016-still active [127]
Prostate Cancer MNPs Injection NCT02033447 Early Phase 1 2013-2017 [131]
Liver Tumor
- ThermoDox®
NCT02181075 Phase 1 2014-2017 [133]- Magnetic resonance high
intensity focused ultrasound
Pediatric Cancer Solid
Tumors
- ThermoDox®
NCT02536183 Phase 1 2015-still active [136]- MRI
- High-intensity focused
ultrasound
Colon Cancer - ThermoDox®
NCT01464593 Phase 2 2011-2016 [137]Liver Metastasis - Radiofrequency ablation
Hepatocellular Carcinoma - ThermoDox® NCT02112656 Phase 3 2014-still active [138]- Radiofrequency ablation
Breast Cancer
- ThermoDox®
NCT00826085 Phase 2 2009-2017 [139]- Microwave hyperthermia
Breast Cancer
- ThermoDox®
NCT03749850 Phase 1 November
2018-still active
[140]- MR-HIFU induced
hyperthermia
- Cyclophosphamide
- IDA - Ferumoxytol
NCT01155388 Phase 3 2017-still active [141]- Non-dialysis-dependent
CKD - Oral Iron
3. Conclusions
Thermosensitive materials are very promising for biomedical treatments. However, much work
remains to be done to solve its main limitations and facilitate its transfer to the clinic. In this context,
one of the most important drawbacks of these nanoparticles is the cleareance and prolonged tissue
retention which can cause toxicity. Moreover, some nanoparticles fail to overcome biological barriers
end up accumulating in organs outside the target, such as the liver and spleen. This produces a
non-specific distribution that negatively affects the diagnosis and treatment of tumors, since when
generating hyperthermia, collateral damage in healthy organs cannot be avoided. Furthermore, for the
use of MNPs combined with images of multiple modalities to be effective and simplify the non-invasive
monitoring of treatments, a dose of MNPs particles necessary to produce the heating should be lowered
so as not to cause saturation of the transverse relaxation time of MRI.
After having carried out an exhaustive search on the clinical trials that have been or are
being developed on thermosensitive materials, we can conclude that (i) thermosensitive materials,
particularly biosensors investigated for analytical and diagnostic applications (e.g., metal-based
nanoparticles, thermosensitive polymers, thermoresponsive nanocomposites, and thermochromic
dyes) have not reached the clinical trial phase yet. Indeed, all clinical trials consulted focus on the use
of ferumoxytol as a current imaging test enhancer except for two newly started trials in September
2018. The first one uses MNPs in the treatment of infertility, and the second one investigates the
safety of carbon black and graphene nanoparticles. None of the existing trials take advantage of the
thermosensitive characteristics of nanoparticles. (ii) In the field of treatment, the thermosensitive
characteristics of nanomaterials are being further exploited especially for the delivery of antitumor
drugs. In this regard, ThermoDox®based on lysolipid thermally sensitive liposome technology to
encapsulate DOX is the flagship drug. Currently, at the preclinical level, other liposomal formulations
such as thermosensitive liposomal nanoparticle (TSLnp) loaded by GEM and paclitaxel (PLX) are
under study for theranostic use in solid tumors. TSLnps significantly improved GEM and PLX delivery
and enhanced its antitumor activity [50,142]. However, the formulation of Gd-TSLnp needs to be fully
optimized to significantly enhance MRI contrast in tumor [50]. Moreover, multiple nano-liposomal
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systems have been successfully developed for drug delivery for non-tumoral pathologies, such as
ocular diseases [143]. Other diseases like IDA, diabetes, and ischemic heart disease are also a target;
pathologies are being treated by thermosensitive nanoparticles using USPIOs, fragment-related peptide
to GNPs (C19-A3 GNP), and iron oxide-labeled mesenchymal stromal cells, respectively.
The discrepancy existing between the number of papers published on thermosensitive
nanomaterials and the number of nanomaterials in clinical use could be due to several factors. On
the one hand, there is the relative novelty of this area of research; the first manuscript related to
thermosensitive nanoparticles published in PubMed is based on data from 2002, hence the need for a
period of time for its validation through clinical trials before its clinical application. On the other hand,
the complexity of thermo-nanocarriers prevents their use in delivering drugs. Indeed, reformulating
most currently approved drugs, in nanosize form will provide a small improvement in performance
that does not compensate for the efforts made by and the costs to pharmaceutical companies. This
has already been observed in other areas of research in the field of nanomedicine [144,145]. However,
we have no doubt that in the coming years there will be an explosion of clinical trials related to
thermosensitive nanomaterials that will surely help to improve current treatments and above all will
impact on patients’ quality of life and life expectancy.
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